Drug Discovery Market Size, Share and Trends by 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Drug Discovery Market Size Analysis

Global Drug Discovery Market Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value
U.S.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Small Molecule Drugs
    1. By Value
  3. Biologic Drugs
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-Throughput Screening (HTS)
    1. By Value
  3. Bioinformatics & In-Silico Modelling
    1. By Value
  4. Computational Drug Discovery & Drug Design
    1. By Value
  5. Nanotechnology
    1. By Value
  6. Others
    1. By Value
3. By End-user
  1. Introduction
    1. End-user By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value
U.K.
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Small Molecule Drugs
    1. By Value
  3. Biologic Drugs
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-Throughput Screening (HTS)
    1. By Value
  3. Bioinformatics & In-Silico Modelling
    1. By Value
  4. Computational Drug Discovery & Drug Design
    1. By Value
  5. Nanotechnology
    1. By Value
  6. Others
    1. By Value
3. By End-user
  1. Introduction
    1. End-user By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value
China
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Small Molecule Drugs
    1. By Value
  3. Biologic Drugs
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-Throughput Screening (HTS)
    1. By Value
  3. Bioinformatics & In-Silico Modelling
    1. By Value
  4. Computational Drug Discovery & Drug Design
    1. By Value
  5. Nanotechnology
    1. By Value
  6. Others
    1. By Value
3. By End-user
  1. Introduction
    1. End-user By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value
UAE
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Small Molecule Drugs
    1. By Value
  3. Biologic Drugs
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-Throughput Screening (HTS)
    1. By Value
  3. Bioinformatics & In-Silico Modelling
    1. By Value
  4. Computational Drug Discovery & Drug Design
    1. By Value
  5. Nanotechnology
    1. By Value
  6. Others
    1. By Value
3. By End-user
  1. Introduction
    1. End-user By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Drug Type
1. Introduction
  1. Drug Type By Value
2. Small Molecule Drugs
  1. By Value
3. Biologic Drugs
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. High-Throughput Screening (HTS)
  1. By Value
3. Bioinformatics & In-Silico Modelling
  1. By Value
4. Computational Drug Discovery & Drug Design
  1. By Value
5. Nanotechnology
  1. By Value
6. Others
  1. By Value
By End-user
1. Introduction
  1. End-user By Value
2. Pharmaceutical Companies
  1. By Value
3. Contract Research Organizations
  1. By Value
4. Others
  1. By Value
Brazil
1. By Drug Type
  1. Introduction
    1. Drug Type By Value
  2. Small Molecule Drugs
    1. By Value
  3. Biologic Drugs
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. High-Throughput Screening (HTS)
    1. By Value
  3. Bioinformatics & In-Silico Modelling
    1. By Value
  4. Computational Drug Discovery & Drug Design
    1. By Value
  5. Nanotechnology
    1. By Value
  6. Others
    1. By Value
3. By End-user
  1. Introduction
    1. End-user By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Contract Research Organizations
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Drug Discovery Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
GlaxoSmithKline PLC
Merck and Co. Inc.
Agilent Technologies Inc.
Eli Lilly and Company
Hoffmann-La Roche Ltd
Bayer AG
Abbott Laboratories Inc.
Shimadzu Corp
AstraZeneca
Sanofi
Polpharma Biologics Group
Novartis AG
Takeda Pharmaceutical Company Limited.
Teva Pharmaceutical Industries Ltd.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment